Mupirocin calcium dihydrate

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 574479

CAS#: 115074-43-6 (calcium)

Description: Mupirocin calcium dihydrate is an antibiotic and bacterial metabolite. It is bacteriostatic against S. aureus (MIC = 0.05 µg/ml) and active against skin wound clinical isolates of methicillin-resistant S. aureus (MRSA; MICs = 1-4 µg/ml). Mupirocin inhibits MRSA and P. aeruginosa biofilm formation in vitro.4 It inhibits bacterial cell wall isoleucyl-tRNA synthetase, slowing bacterial growth. Topical administration of Mupirocin (2% v/v) reduces the number of wound colony forming units (CFUs) in a mouse model of MRSA skin infection. Lithium mupirocin as been used to study mupirocin resistance in staphylococcus aureus and in mycoplasma susceptibility studies.

Chemical Structure

Mupirocin calcium dihydrate
CAS# 115074-43-6 (calcium)

Theoretical Analysis

MedKoo Cat#: 574479
Name: Mupirocin calcium dihydrate
CAS#: 115074-43-6 (calcium)
Chemical Formula: C52H90CaO20
Exact Mass: 1074.5651
Molecular Weight: 1075.35
Elemental Analysis: C, 58.08; H, 8.44; Ca, 3.73; O, 29.76

Price and Availability

Size Price Availability Quantity
200.0mg USD 750.0 2 Weeks
Bulk inquiry

Related CAS #: 12650-69-0 (free acid)   73346-79-9 (lithium)   115074-43-6 (calcium)    

Synonym: Mupirocin calcium salt; Calcium Mupirocin Dihydrate; Mupirocin Calcium Hydrate

IUPAC/Chemical Name: calcium 9-(((E)-4-((2S,3R,4R,5S)-3,4-dihydroxy-5-(((2S,3S)-3-((2S,3S)-3-hydroxybutan-2-yl)oxiran-2-yl)methyl)tetrahydro-2H-pyran-2-yl)-3-methylbut-2-enoyl)oxy)nonanoate dihydrate


InChi Code: InChI=1S/2C26H44O9.Ca.2H2O/c2*1-16(13-23(30)33-11-9-7-5-4-6-8-10-22(28)29)12-20-25(32)24(31)19(15-34-20)14-21-26(35-21)17(2)18(3)27;;;/h2*13,17-21,24-27,31-32H,4-12,14-15H2,1-3H3,(H,28,29);;2*1H2/q;;+2;;/p-2/b2*16-13+;;;/t2*17-,18-,19-,20-,21-,24+,25-,26-;;;/m00.../s1

SMILES Code: O.O.[Ca+2].C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@H]2CO[C@@H](C\C(=C\C(=O)OCCCCCCCCC(=O)[O-])\C)[C@H](O)[C@@H]2O.C[C@H](O)[C@H](C)[C@@H]3O[C@H]3C[C@H]4CO[C@@H](C\C(=C\C(=O)OCCCCCCCCC(=O)[O-])\C)[C@H](O)[C@@H]4O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 1075.35 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Isaacson G. Oxymetazoline, Mupirocin, Clotrimazole-Safe, Effective, Off-Label Agents for Tympanostomy Tube Care. Ear Nose Throat J. 2020 Nov;99(1_suppl):30S-34S. doi: 10.1177/0145561320912885. Epub 2020 Mar 17. PMID: 32182136.

2: Dadashi M, Hajikhani B, Darban-Sarokhalil D, van Belkum A, Goudarzi M. Mupirocin resistance in Staphylococcus aureus: A systematic review and meta- analysis. J Glob Antimicrob Resist. 2020 Mar;20:238-247. doi: 10.1016/j.jgar.2019.07.032. Epub 2019 Aug 20. PMID: 31442624.

3: Tucaliuc A, Blaga AC, Galaction AI, Cascaval D. Mupirocin: applications and production. Biotechnol Lett. 2019 May;41(4-5):495-502. doi: 10.1007/s10529-019-02670-w. Epub 2019 Mar 29. PMID: 30927135.

4: Khoshnood S, Heidary M, Asadi A, Soleimani S, Motahar M, Savari M, Saki M, Abdi M. A review on mechanism of action, resistance, synergism, and clinical implications of mupirocin against Staphylococcus aureus. Biomed Pharmacother. 2019 Jan;109:1809-1818. doi: 10.1016/j.biopha.2018.10.131. Epub 2018 Nov 26. PMID: 30551435.

5: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006–. Mupirocin. 2018 Oct 31. PMID: 30000489.

6: Bari O, Cohen PR. Successful Management of Zoon's Balanitis with Topical Mupirocin Ointment: A Case Report and Literature Review of Mupirocin-Responsive Balanitis Circumscripta Plasmacelluaris. Dermatol Ther (Heidelb). 2017 Jun;7(2):203-210. doi: 10.1007/s13555-017-0178-1. Epub 2017 Apr 5. Erratum in: Dermatol Ther (Heidelb). 2017 Jun;7(2):211. PMID: 28382428; PMCID: PMC5453920.

7: Tsai CC, Yang PS, Liu CL, Wu CJ, Hsu YC, Cheng SP. Comparison of topical mupirocin and gentamicin in the prevention of peritoneal dialysis-related infections: A systematic review and meta-analysis. Am J Surg. 2018 Jan;215(1):179-185. doi: 10.1016/j.amjsurg.2017.03.005. Epub 2017 Mar 15. PMID: 28341139.

8: Lee MA, Cohen PR. Zoon Balanitis Revisited: Report of Balanitis Circumscripta Plasmacellularis Resolving With Topical Mupirocin Ointment Monotherapy. J Drugs Dermatol. 2017 Mar 1;16(3):285-287. PMID: 28301626.

9: George S, Leasure AR, Horstmanshof D. Effectiveness of Decolonization With Chlorhexidine and Mupirocin in Reducing Surgical Site Infections: A Systematic Review. Dimens Crit Care Nurs. 2016 Jul-Aug;35(4):204-22. doi: 10.1097/DCC.0000000000000192. PMID: 27258958.

10: Hetem DJ, Bootsma MC, Bonten MJ. Prevention of Surgical Site Infections: Decontamination With Mupirocin Based on Preoperative Screening for Staphylococcus aureus Carriers or Universal Decontamination? Clin Infect Dis. 2016 Mar 1;62(5):631-6. doi: 10.1093/cid/civ990. Epub 2015 Dec 9. PMID: 26658054.

11: Greywal T, Cohen PR. Pitted keratolysis: successful management with mupirocin 2% ointment monotherapy. Dermatol Online J. 2015 Aug 15;21(8):13030/qt6155v9wk. PMID: 26437161.

12: Agarwal A, Nesrallah G. Long-Term Safety of Buttonhole Cannulation and Efficacy of Mupirocin Prophylaxis. Contrib Nephrol. 2015;186:64-70. doi: 10.1159/000431162. Epub 2015 Aug 5. PMID: 26283561.

13: Poovelikunnel T, Gethin G, Humphreys H. Mupirocin resistance: clinical implications and potential alternatives for the eradication of MRSA. J Antimicrob Chemother. 2015 Oct;70(10):2681-92. doi: 10.1093/jac/dkv169. Epub 2015 Jul 3. PMID: 26142407.

14: Hetem DJ, Bonten MJ. Clinical relevance of mupirocin resistance in Staphylococcus aureus. J Hosp Infect. 2013 Dec;85(4):249-56. doi: 10.1016/j.jhin.2013.09.006. Epub 2013 Sep 21. PMID: 24144552.

15: Gurney R, Thomas CM. Mupirocin: biosynthesis, special features and applications of an antibiotic from a gram-negative bacterium. Appl Microbiol Biotechnol. 2011 Apr;90(1):11-21. doi: 10.1007/s00253-011-3128-3. Epub 2011 Feb 20. PMID: 21336932.

16: Thomas CM, Hothersall J, Willis CL, Simpson TJ. Resistance to and synthesis of the antibiotic mupirocin. Nat Rev Microbiol. 2010 Apr;8(4):281-9. doi: 10.1038/nrmicro2278. Epub 2010 Mar 1. PMID: 20190824.

17: Xu G, Tu W, Xu C. Mupirocin for preventing exit-site infection and peritonitis in patients undergoing peritoneal dialysis. Nephrol Dial Transplant. 2010 Feb;25(2):587-92. doi: 10.1093/ndt/gfp411. Epub 2009 Aug 13. PMID: 19679557.

18: Patel JB, Gorwitz RJ, Jernigan JA. Mupirocin resistance. Clin Infect Dis. 2009 Sep 15;49(6):935-41. doi: 10.1086/605495. PMID: 19673644.

19: Coates T, Bax R, Coates A. Nasal decolonization of Staphylococcus aureus with mupirocin: strengths, weaknesses and future prospects. J Antimicrob Chemother. 2009 Jul;64(1):9-15. doi: 10.1093/jac/dkp159. Epub 2009 May 18. PMID: 19451132; PMCID: PMC2692503.

20: van Rijen M, Bonten M, Wenzel R, Kluytmans J. Mupirocin ointment for preventing Staphylococcus aureus infections in nasal carriers. Cochrane Database Syst Rev. 2008 Oct 8;(4):CD006216. doi: 10.1002/14651858.CD006216.pub2. PMID: 18843708.